Transasia Bio-Medicals Ltd, a Mumbai-based diagnostic company, has acquired European company Pliva Lachema Diagnostika. Lachema is engaged in production and marketing of ‘in vitro diagnostics’ products for urine analysis, biochemistry and microbiology.
Transasia has acquired the company through its German subsidiary Erba Diagnostics Mannheim GmbH, it said in a statement. However, it did not disclose about the financials of the transaction. Lachema has presence in central and eastern Europe, and has manufacturing and R&D facilities at Brno in Czech Republic.
Transasia stated that the acquisition will help it and its subsidiary to usher in newer products for the developing markets in Asia. “Lachema’s customers in central and eastern Europe will have access to Transasia’s extensive product range in clinical chemistry, immunoturbidimetry and immunology,” said the company.
The company further plans to invest over $1 million in Lachema to increase its manufacturing capacities and add new products. Transasia manufactures diagnostic instruments and reagents for clinical diagnosis in the field of biochemistry, haematology, immunology, critical care, coagulation, urine analysis, liquid handling systems and blood transfusion medicine.